Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds

The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein–protein interactions. We have refined crystallization conditions for KRAS(169)(Q61H)-yielding crystals suitable for soaking...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz-Migoni, Abimael, Canning, Peter, Quevedo, Camilo E., Bataille, Carole J. R., Bery, Nicolas, Miller, Ami, Russell, Angela J., Phillips, Simon E. V., Carr, Stephen B., Rabbitts, Terence H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2019
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377466/
https://www.ncbi.nlm.nih.gov/pubmed/30683716
http://dx.doi.org/10.1073/pnas.1811360116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377466/
https://www.ncbi.nlm.nih.gov/pubmed/30683716
http://dx.doi.org/10.1073/pnas.1811360116

Ejemplares similares